Bifogade filer
PDF
Kurs & Likviditet
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Spotlight |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Spermosens AB today announces that the European Patent Office (EPO) has granted the patent EP 3 768 825, which protects the company's biosensor and its use for in vitro fertilization. The formal grant follows the previous "Intention to Grant"-notification communicated April 16[th] 2021.
Based on EPO:s grant of the patent with number EP 3 768 825, a European protection exists until 2039 and encompasses the company's biosensor product and its use for, e.g. detecting and quantifying sperm binding function, diagnosis of male infertility, and selection of sperms suitable for In Vitro Fertilization (IVF) purposes. The formal date of grant of the European patent is August 11[th] 2021.
Spermosens has corresponding patent applications pending in Australia, Brazil, Canada, China, Eurasia (including Russia), Hong Kong, Israel, India, Japan, Mexico, New Zealand, Singapore, South Korea, South Africa and the USA.
"Spermosens, which has been listed on Spotlight for slightly more than two months, aims to provide a game changing technology for couples undergoing IVF treatment. With EPO's decision to grant, Spermosens has obtained a first and strong patent protection for its product in the important home market. This provides stable and robust protection for our product candidates and their use.", says John Lempert, CEO of Spermosens.
For further information, please contact:
John Lempert, VD
+46 (0)76-311 40 91
info@spermosens.com
This information is such that Spermosens AB is obligated to disclose pursuant to the EU Market Abuse Regulation. The information was published, through the agency of the contact persons mentioned above, at 9:05 am on 15[th] of July 2021.
Spermosens AB (publ)
www.spermosens.com
Spermosens, founded in 2018, develops medical devices for male infertility, to individualize and adapt In Vitro Fertilization treatments. The patent-pending technology is based on the discovery of the JUNO protein in egg cells by two independent research groups. Spermosens' first product, JUNO-Checked, consists of two components: a measuring instrument with associated software, as well as disposable chips. The measuring instrument analyzes the sperm applied to the chip and finds out the binding capacity to the egg cell, which enables an individualized choice of appropriate fertility treatment based on the measured binding capacity.